Nexalin Technology (NXL) Change in Accured Expenses (2022 - 2026)
Nexalin Technology's quarterly Change in Accured Expenses came in at -$2489.0 in Q1 2026, down 195.84% year-on-year from $2597.0 in Q1 2025, and down 100.78% quarter-over-quarter from $318723.0 in Q4 2025.
Nexalin Technology has reported Change in Accured Expenses for 5 years, with the latest figure at -$2489.0 in Q1 2026.
- For the quarter ending Q1 2026, Change in Accured Expenses fell 195.84% year-over-year to -$2489.0; the trailing twelve-month figure through Mar 2026 stood at $246923.0 (up 556.2% YoY), and the FY2025 full-year result was $252009.0, up 94.66% from the prior year.
- Change in Accured Expenses for Q1 2026 stood at -$2489.0, down from $318723.0 in the prior quarter.
- The five-year high for Change in Accured Expenses was $318723.0 in Q4 2025, with the low at -$230747.0 in Q2 2024.
- Average Change in Accured Expenses over 5 years is $18502.9, with a median of $5973.0 recorded in 2023.
- Year-over-year, Change in Accured Expenses jumped 316.82% in 2023 and plunged 3963.17% in 2024.
- Tracing NXL's Change in Accured Expenses over 5 years: stood at $97322.0 in 2022, then slumped by 336.95% to -$230607.0 in 2023, then surged by 211.83% to $257898.0 in 2024, then advanced by 23.58% to $318723.0 in 2025, then sank by 100.78% to -$2489.0 in 2026.
- The last three Change in Accured Expenses figures came in at -$2489.0 (Q1 2026), $318723.0 (Q4 2025), and -$47973.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | - |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | -654.00 Mn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | 703.00 Mn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | -512.00 Mn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | -347.10 Mn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 21.07 Mn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 145.10 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | -250.00 Mn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 74.30 Mn |
| 10 | Nexalin Technology | 11.19 Mn | 8.48 Mn | 13,133.00 | -2,489.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2,489.00 |
| Mar 31, 2026 | -2,489.00 |
| Dec 31, 2025 | 318,723.00 |
| Dec 31, 2025 | 318,723.00 |
| Sep 30, 2025 | -47,973.00 |
| Sep 30, 2025 | -47,973.00 |
| Jun 30, 2025 | -21,338.00 |
| Jun 30, 2025 | -21,338.00 |
| Mar 31, 2025 | 2,597.00 |
| Mar 31, 2025 | 2,597.00 |
| Dec 31, 2024 | 257,898.00 |
| Dec 31, 2024 | 257,898.00 |
| Sep 30, 2024 | 7,881.00 |
| Sep 30, 2024 | 7,881.00 |
| Jun 30, 2024 | -230,747.00 |
| Jun 30, 2024 | -230,747.00 |
| Mar 31, 2024 | 94,429.00 |
| Mar 31, 2024 | 94,429.00 |
| Dec 31, 2023 | -230,607.00 |
| Dec 31, 2023 | -230,607.00 |
| Sep 30, 2023 | 3,258.00 |
| Sep 30, 2023 | 3,258.00 |
| Jun 30, 2023 | 5,973.00 |
| Jun 30, 2023 | 5,973.00 |
| Mar 31, 2023 | 57,838.00 |
| Mar 31, 2023 | 57,838.00 |
| Dec 31, 2022 | 97,322.00 |
| Dec 31, 2022 | 97,322.00 |
| Sep 30, 2022 | 13,835.00 |
| Sep 30, 2022 | 13,835.00 |
| Jun 30, 2022 | 14,625.00 |
| Jun 30, 2022 | 14,625.00 |
| Mar 31, 2022 | -26,675.00 |
| Mar 31, 2022 | -26,675.00 |